| Version | |
| Categories | Manuscript Data, MOA Hypothesis 2011, MOA Small Intestine 2013, Original Data, Risk Assessment, Rodent PBPK |
| Download | 517 |
| Size | 8.88 MB |
| Create Date | March 20, 2014 |
| Last Updated | March 21, 2014 |
Play List
Used in:
- Figures 4, 6, and Tables 1, 2 from Thompson et al. (2011), Application of the U.S. EPA Mode of Action Framework for Purposes of Guiding Future Research: A Case Study Involving the Oral Carcinogenicity of Hexavalent Chromium;
- Figures 1, 4, 5, 6, 10 from Kirman et al. (2012), Physiologically based pharmacokinetic model for rats and mice orally exposed to chromium;
- Figure 10 and Table 3 from Thompson et al. (2013), Assessment of the mode of action underlying development of rodent small intestinal tumors following oral exposure to hexavalent chromium and relevance to humans;
- Figure 1 and Table 3 from Thompson et al. (2013), A chronic oral reference dose for hexavalent chromium-induced intestinal cancer.